Similar articles

• The evaluation of cytotoxic drugs.

  Von Hoff DD, Rozencweig M, Muggia FM. Von Hoff DD, et al. Cancer Treat Rev. 1979 Jun;6 Suppl:1-8. doi: 10.1016/s0305-7372(79)80004-3. Cancer Treat Rev. 1979. PMID: 498161 No abstract available.
• New strategies in cancer chemotherapy.

  Bonadonna G. Bonadonna G. Cell Biophys. 1986 Dec;9(1-2):243-56. doi: 10.1007/BF02797385. Cell Biophys. 1986. PMID: 2436797 No abstract available.
• Clinical development of anticancer agents--a National Cancer Institute perspective.

  Marsoni S, Wittes R. Marsoni S, et al. Cancer Treat Rep. 1984 Jan;68(1):77-85. Cancer Treat Rep. 1984. PMID: 6362870 Clinical Trial. No abstract available.
• Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions.

  Venditti JM, Wesley RA, Plowman J. Venditti JM, et al. Adv Pharmacol Chemother. 1984;20:1-20. doi: 10.1016/s1054-3589(08)60263-x. Adv Pharmacol Chemother. 1984. PMID: 6398966 Review. No abstract available.
• [The individualized therapy of tumors].

  Mattern J, Volm M. Mattern J, et al. Dtsch Med Wochenschr. 1992 Oct 30;117(44):1685-9. doi: 10.1055/s-2008-1062499. Dtsch Med Wochenschr. 1992. PMID: 1425274 Review. German. No abstract available.